Literature DB >> 33616856

Immune-mediated thrombotic thrombocytopenic purpura in childhood treated by caplacizumab, about 3 cases.

Julie Boudali1, Benjamin Hallak2, Marie Haeck3, Anne-Laure Sellier-Leclerc4, Marc Ulrich3, Paul Coppo5, Stéphanie Tellier2, François Provôt6.   

Abstract

Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare disease in adults and exceptional in childhood. Caplacizumab has proven its effectiveness in the treatment of iTTP in adulthood in association with standard of care. Unfortunately, this treatment is restricted to adults. We report our experience in three children who were treated successfully with caplacizumab.
© 2021. Italian Society of Nephrology.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33616856     DOI： 10.1007/s40620-021-00992-5

Source DB:  PubMed          Journal:  J Nephrol        ISSN： 1121-8428            Impact factor:   3.902


  1 in total

1.  Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group.

Authors:  Fadi Fakhouri; Marie Scully; François Provôt; Miquel Blasco; Paul Coppo; Marina Noris; Kathy Paizis; David Kavanagh; Frédéric Pène; Sol Quezada; Alexandre Hertig; Sébastien Kissling; Patrick O'Brien; Yahsou Delmas; Lorenzo Alberio; Norbert Winer; Agnès Veyradier; Spero Cataland; Véronique Frémeaux-Bacchi; Chantal Loirat; Giuseppe Remuzzi; Vassilis Tsatsaris
Journal:  Blood       Date:  2020-11-05       Impact factor: 22.113
  1 in total
  3 in total

1.  Thrombotic thrombocytopenic purpura temporally associated with BNT162b2 vaccination in an adolescent successfully treated with caplacizumab.

Authors:  Amrit Kirpalani; Justin Garabon; Kiersten Amos; Serina Patel; Ajay P Sharma; Saptharishi Lalgudi Ganesan; Michelle Barton; Chantel Cacciotti; Sarah Leppington; Linda Bakovic; Shih-Han Susan Huang; Michael J Knauer; Soumitra Tole
Journal:  Br J Haematol       Date:  2021-08-17       Impact factor: 8.615

2.  Off-label caplacizumab as add-on therapy in a 9-year-old boy with refractory aTTP.

Authors:  Marinella Veltroni; Francesco Pegoraro; Barbara Scappini; Francesca Brugnolo; Elisa Allegro; Stefano Ermini; Annalisa Tondo; Ilaria Fotzi; Franco Bambi; Claudio Favre
Journal:  Ann Hematol       Date:  2021-12-21       Impact factor: 3.673

3.  Caplacizumab Model-Based Dosing Recommendations in Pediatric Patients With Acquired Thrombotic Thrombocytopenic Purpura.

Authors:  Martin Bergstrand; Emma Hansson; Bernard Delaey; Filip Callewaert; Rui De Passos Sousa; Maria Laura Sargentini-Maier
Journal:  J Clin Pharmacol       Date:  2021-11-29       Impact factor: 2.860
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.